death penalty attention getter

  • Publications
  • Archives
  • BCIQ
  • Conferences
  • Free Trial /
    Subscribe
  • Sign In
  • English
  • 简体中文
  • 日本語
  • 한국어

Biocentury

// BCIQ

Menu
Menu


  • Home
    Today

  • Publications
    Publications

    • Publications Home
    • BioCentury
    • BC Innovations
    • BC Extra
    • BC Week In Review
    • Current Issues
  • Archives
    Archives

    • Archives Home
    • Basic Search
    • Advanced Search
    • Back Issues
  • BCIQ
    BCIQ

    • BCIQ Home
    • Overview
    • Newsfeed
    • Companies
    • Products
    • Finance
    • Deals
  • Conferences
    Conferences

    • Conferences Home
    • Newsmakers
    • Bio€quity Europe
    • Future Leaders
    • China Healthcare Summit
    • Other Industry Events
  • eLearning
    Interact

    • eLearning Home
    • Videos
    • White Papers
    • Follow Us

      Twitter

      LinkedIn

      RSS

X

  • Newsfeed

  • Companies

  • Products

  • Finance

  • Deals

  • Profile Reports




  • Overview
  • Pipeline
  • Deals
  • Financings
  • Earnings Summary
  • Stock Summary
  • Articles

214 documents

  • BioCentury 84

      • Product Development 2

      • Regulation 2

      • Finance 67

      • Distillery Therapeutics 1

  • BC Extra 59

      • Clinical News 5

      • Top Story 4

  • BC Week In Review 70

      • Clinical News 34

      • Regulatory 17
      • Clinical Results 13
      • Clinical Status 4
        Read All
  • 22:45 ,
    Jun 20, 2018 | 
    BC Extra  | 
    Company News

    Management tracks: Impel, InGeneron

    Drug delivery company Impel NeuroPharma Inc. (Seattle, Wash.) named Jon Congleton president and CEO. He was president and CEO at Nivalis Therapeutics Inc. , which merged with Alpine Immune Sciences Inc. (NASDAQ:ALPN). Regenerative medicine company…

    Read More

    21:32 ,
    Sep 29, 2017 | 
    BC Week In Review  | 
    Company News

    Aegerion to pay fine for Juxtapid violations

    Aegerion Pharmaceuticals Inc. will pay more than $40 million to the SEC and the U.S. Department of Justice to resolve allegations associated with Juxtapid lomitapide. The drug was approved in the U.S. in 2012 as…

    Read More

    00:38 ,
    Apr 1, 2017 | 
    BC Extra  | 
    Company News

    Amryt, Aegerion deal

    Aegerion granted Amryt exclusive rights to market Lojuxta lomitapide in the European Economic Area (EEA), Middle East and North Africa (MENA), Israel and Turkey. Aegerion is eligible for milestone payments, plus royalties. Amryt will be…

    Read More

    00:06 ,
    Dec 3, 2016 | 
    BC Extra  | 
    Company News

    Juxtapid regulatory update

    Aegerion said Japan approved Juxtapid lomitapide to treat patients with homozygous familial hypercholesterolemia (HoFH). The product is a small molecule microsomal triglyceride transfer protein ( MTTP ; MTP) inhibitor and is approved in the U.S….

    Read More

    07:00 ,
    Oct 3, 2016 | 
    BioCentury  | 
    Finance

    ASH and others

    Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less…

    Read More

    About Biocentury
    • Company Overview
    • Management
    • Editorial & Research
    • Market data
    Contact
    • Contact Us
    • Advertising & Sponsorship
    • Career Opportunities
    Support
    • Customer Service
    • Reprints
    • FAQs
    Products & Solutions
    • Products Overview
    • Publications
    • Archives
    • BCIQ
    • Conferences
    • eLearning
    • RSS Feeds
    Legal
    • User Agreement
    • Terms of Use
    • Privacy Policy
    • Your California Privacy Rights
    • Use of Images
    • Market data
    • Follow Us

      Twitter

      LinkedIn

      RSS

    © 2018 BioCentury Inc. All Rights Reserved.
      
    Terms & Conditions |
    Privacy Policy